The International Symposium on Minimal Residual Cancer (ISMRC) is a premier global event focusing on the latest advancements in liquid biopsy and cancer diagnostics. Since its inception in 1996, ISMRC has become a pivotal forum for scientists, clinicians, and innovators dedicated to early cancer detection and treatment monitoring. Congress chairs include Prof. Dr. Paul Hofman (France), Prof. Dr. Catherine Alix-Panabières (France), and Prof. Dr. Klaus Pantel (Germany), all esteemed figures in the field of liquid biopsy.
We are proud to announce that our Chief Scientific Officer, Veronique Calleja, will be attending ISMRC 2025. Her participation underscores our commitment to advancing cancer diagnostics and engaging with the forefront of scientific research.
Additionally, we are honored that Dr. Paul Hofman, one of the congress chairs, serves on our Scientific Advisory Board. His leadership at ISMRC 2025 and his ongoing collaboration with our team highlight our shared dedication to innovation in oncology.
This project has been co-funded by the European Union’s Horizon Europe research and innovation programme under grant agreement Nº101161495.
“Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.”
Stay connected
Subscribe to the HAWK Biosystems newsletter and don’t miss any news about our company, our products, events and much more.